公开(公告)号：US20230348548A1

公开(公告)日：2023-11-02

申请号：US18309080

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Mohammad HOSSAIN ,  Gagan BAJWA ,  Melinda MATA ,  Mamta KALRA

IPC: C12N5/0783 ,  C12N15/86 ,  C07K14/705 ,  C07K16/00 ,  C07K14/54 ,  C07K14/725 ,  A61K39/00 ,  A61K39/39

CPC classification number: C07K14/5443 ,  A61K39/39 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4621 ,  A61K39/4632 ,  A61K39/4633 ,  A61K39/4635 ,  A61K39/4643 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/00 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55588 ,  C12N2502/1121 ,  C12N2740/15043

Abstract: The present disclosure relates to cells capable of co-expressing T cell receptors (“TCR”) together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15Rα, IL-15/IL-15Rα fusion polypeptide, and IL-15Rα/IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.

公开(公告)号：US20230348561A1

公开(公告)日：2023-11-02

申请号：US18309062

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Erik FARRAR ,  Justin GUNESCH ,  Melinda MATA ,  Mohammad HOSSAIN ,  Mamta KALRA ,  Gagan BAJWA

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/63 ,  A61P37/04

CPC classification number: C07K14/7051 ,  C07K14/70517 ,  C12N15/63 ,  A61P37/04

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with dominant negative TGFβ Receptor (“dnTGFβR”) polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for dnTGFβR polypeptides, vectors, and associated methods thereof. The present disclosure further provides for modified CD8 polypeptides, vectors, and associated methods of making and using the same.

公开(公告)号：US20240066127A1

公开(公告)日：2024-02-29

申请号：US18308427

申请日：2023-04-27

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Melinda MATA ,  Mamta KALRA ,  Gagan BAJWA

IPC: A61K39/00 ,  A61K39/39 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725

CPC classification number: A61K39/4635 ,  A61K39/39 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4632 ,  A61K39/464489 ,  A61P35/00 ,  C07K14/54 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70517 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561

Abstract: The present disclosure relates to cells capable of co-expressing one or any combination of T cell receptors (“TCR”), CD8 polypeptides, interleukin 12 (IL-12) polypeptides, interleukin 15 (IL-15) polypeptides, and/or interleukin 18 (IL-18) polypeptides, and the use thereof in adoptive cellular therapy (“ACT”). The present disclosure further provides for modified CD8 sequences, IL-12 sequences, IL-15 sequences, IL-18 sequences, vectors, compositions, transformed T cells, and associated methods thereof.

公开(公告)号：US20230089392A1

公开(公告)日：2023-03-23

申请号：US17933418

申请日：2022-09-19

Applicant: Immatics US, Inc.

Inventor： Justin GUNESCH ,  Pooja MEHTA ,  Mamta KALRA

IPC: C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74

Abstract: A method for producing an engineered T cell population includes obtaining a cell population containing a monocyte and a T cell, resting the obtained cell population on a surface, adhering the monocyte to the surface, retaining a non-adherent cell population, activating the non-adherent cell population, introducing a nucleic acid into the activated non-adherent cell population to obtain a transformed T cell, and expanding the transformed T cell to obtain the engineered T cell population.